In a report published Tuesday, Goldman Sachs analyst Robert P. Jones downgraded the rating on Charles River Laboratories CRL from Neutral to Sell, and lowered the price target from $44.00 to $38.00.
In the report, Goldman Sachs noted, “We downgrade CRL to Sell as we see risk to guidance for RMS (Research Models) constant currency growth of 4%-6% and see little upside to PCS (Preclinical Services). We see 12% downside to our new $38, 12-month price target vs. 4% downside for our CRO coverage. On PCS, recent results and channel checks indicate still subdued early-stage spend and excess capacity as pharma prioritizes late-stage pipelines. For RMS, we estimate (excluding recent acquisitions) sales declined by 2.5% on a constant currency basis, suggesting flat volume growth. All in, we await a broader rebound in Preclinical demand and downgrade CRL as we see little valuation support.”
Charles River Laboratories closed on Monday at $43.21.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.